This record was last updated September 19, 2024 (before its estimated April 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.